Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer

Long-term follow-up of a large patient cohort

Isamu Okamoto, Satoshi Morita, Naoki Tashiro, Fumio Imamura, Akira Inoue, Takashi Seto, Nobuyuki Yamamoto, Yuichiro Ohe, Kazuhiko Nakagawa, Masahiro Fukuoka

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in clinical trials. However, there is a lack of data from routine clinical practice. This study determined treatment and outcomes in patients with EGFR mutation-positive NSCLC treated in a real world setting. Materials and methods Clinical characteristics, information about NSCLC treatment regimens and survival outcomes data were obtained retrospectively from 17 medical centers across Japan. In addition to overall survival (OS), subgroup analyses were conducted based on first- and second-line treatments and combinations, and for patients who had survived >5 years from initiation of first-line treatment. Results The full analysis set comprised 1656 patients (mean 67 years, 80.6% with performance status 0 or 1). Median follow-up was 29.5 months and median OS was 29.7 months; 3- and 5-year survival rates were 41.2% and 21.5%, respectively. Significant predictors of OS were younger age, no smoking history, histological diagnosis of adenocarcinoma, less advanced clinical stage, good performance status and major EGFR-activating mutation. Despite some imbalances in baseline characteristics, patients who received first-line chemotherapy had numerically higher 5-year survival rates than those who received first-line EGFR-TKIs. Conclusions This large, long-term analysis of EGFR mutation-positive NSCLC patients provides useful information about treatment outcomes in clinical practice. Updated analyses are required to determine real world outcomes for NSCLC patients treated with the latest available agents, including immunotherapies.

Original languageEnglish
Pages (from-to)14-19
Number of pages6
JournalLung Cancer
Volume117
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Non-Small Cell Lung Carcinoma
Mutation
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Survival
Survival Rate
Therapeutics
Survival Analysis
Immunotherapy
Japan
Adenocarcinoma
Smoking
History
Clinical Trials
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer : Long-term follow-up of a large patient cohort. / Okamoto, Isamu; Morita, Satoshi; Tashiro, Naoki; Imamura, Fumio; Inoue, Akira; Seto, Takashi; Yamamoto, Nobuyuki; Ohe, Yuichiro; Nakagawa, Kazuhiko; Fukuoka, Masahiro.

In: Lung Cancer, Vol. 117, 01.03.2018, p. 14-19.

Research output: Contribution to journalArticle

Okamoto, I, Morita, S, Tashiro, N, Imamura, F, Inoue, A, Seto, T, Yamamoto, N, Ohe, Y, Nakagawa, K & Fukuoka, M 2018, 'Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort', Lung Cancer, vol. 117, pp. 14-19. https://doi.org/10.1016/j.lungcan.2018.01.005
Okamoto, Isamu ; Morita, Satoshi ; Tashiro, Naoki ; Imamura, Fumio ; Inoue, Akira ; Seto, Takashi ; Yamamoto, Nobuyuki ; Ohe, Yuichiro ; Nakagawa, Kazuhiko ; Fukuoka, Masahiro. / Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer : Long-term follow-up of a large patient cohort. In: Lung Cancer. 2018 ; Vol. 117. pp. 14-19.
@article{9a59e16e02e54d66b96cb888470a444d,
title = "Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort",
abstract = "Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in clinical trials. However, there is a lack of data from routine clinical practice. This study determined treatment and outcomes in patients with EGFR mutation-positive NSCLC treated in a real world setting. Materials and methods Clinical characteristics, information about NSCLC treatment regimens and survival outcomes data were obtained retrospectively from 17 medical centers across Japan. In addition to overall survival (OS), subgroup analyses were conducted based on first- and second-line treatments and combinations, and for patients who had survived >5 years from initiation of first-line treatment. Results The full analysis set comprised 1656 patients (mean 67 years, 80.6{\%} with performance status 0 or 1). Median follow-up was 29.5 months and median OS was 29.7 months; 3- and 5-year survival rates were 41.2{\%} and 21.5{\%}, respectively. Significant predictors of OS were younger age, no smoking history, histological diagnosis of adenocarcinoma, less advanced clinical stage, good performance status and major EGFR-activating mutation. Despite some imbalances in baseline characteristics, patients who received first-line chemotherapy had numerically higher 5-year survival rates than those who received first-line EGFR-TKIs. Conclusions This large, long-term analysis of EGFR mutation-positive NSCLC patients provides useful information about treatment outcomes in clinical practice. Updated analyses are required to determine real world outcomes for NSCLC patients treated with the latest available agents, including immunotherapies.",
author = "Isamu Okamoto and Satoshi Morita and Naoki Tashiro and Fumio Imamura and Akira Inoue and Takashi Seto and Nobuyuki Yamamoto and Yuichiro Ohe and Kazuhiko Nakagawa and Masahiro Fukuoka",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.lungcan.2018.01.005",
language = "English",
volume = "117",
pages = "14--19",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer

T2 - Long-term follow-up of a large patient cohort

AU - Okamoto, Isamu

AU - Morita, Satoshi

AU - Tashiro, Naoki

AU - Imamura, Fumio

AU - Inoue, Akira

AU - Seto, Takashi

AU - Yamamoto, Nobuyuki

AU - Ohe, Yuichiro

AU - Nakagawa, Kazuhiko

AU - Fukuoka, Masahiro

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in clinical trials. However, there is a lack of data from routine clinical practice. This study determined treatment and outcomes in patients with EGFR mutation-positive NSCLC treated in a real world setting. Materials and methods Clinical characteristics, information about NSCLC treatment regimens and survival outcomes data were obtained retrospectively from 17 medical centers across Japan. In addition to overall survival (OS), subgroup analyses were conducted based on first- and second-line treatments and combinations, and for patients who had survived >5 years from initiation of first-line treatment. Results The full analysis set comprised 1656 patients (mean 67 years, 80.6% with performance status 0 or 1). Median follow-up was 29.5 months and median OS was 29.7 months; 3- and 5-year survival rates were 41.2% and 21.5%, respectively. Significant predictors of OS were younger age, no smoking history, histological diagnosis of adenocarcinoma, less advanced clinical stage, good performance status and major EGFR-activating mutation. Despite some imbalances in baseline characteristics, patients who received first-line chemotherapy had numerically higher 5-year survival rates than those who received first-line EGFR-TKIs. Conclusions This large, long-term analysis of EGFR mutation-positive NSCLC patients provides useful information about treatment outcomes in clinical practice. Updated analyses are required to determine real world outcomes for NSCLC patients treated with the latest available agents, including immunotherapies.

AB - Objectives Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been shown to be effective for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) in clinical trials. However, there is a lack of data from routine clinical practice. This study determined treatment and outcomes in patients with EGFR mutation-positive NSCLC treated in a real world setting. Materials and methods Clinical characteristics, information about NSCLC treatment regimens and survival outcomes data were obtained retrospectively from 17 medical centers across Japan. In addition to overall survival (OS), subgroup analyses were conducted based on first- and second-line treatments and combinations, and for patients who had survived >5 years from initiation of first-line treatment. Results The full analysis set comprised 1656 patients (mean 67 years, 80.6% with performance status 0 or 1). Median follow-up was 29.5 months and median OS was 29.7 months; 3- and 5-year survival rates were 41.2% and 21.5%, respectively. Significant predictors of OS were younger age, no smoking history, histological diagnosis of adenocarcinoma, less advanced clinical stage, good performance status and major EGFR-activating mutation. Despite some imbalances in baseline characteristics, patients who received first-line chemotherapy had numerically higher 5-year survival rates than those who received first-line EGFR-TKIs. Conclusions This large, long-term analysis of EGFR mutation-positive NSCLC patients provides useful information about treatment outcomes in clinical practice. Updated analyses are required to determine real world outcomes for NSCLC patients treated with the latest available agents, including immunotherapies.

UR - http://www.scopus.com/inward/record.url?scp=85040241844&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040241844&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2018.01.005

DO - 10.1016/j.lungcan.2018.01.005

M3 - Article

VL - 117

SP - 14

EP - 19

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

ER -